Is Febuxostat Use Associated With Increased Risk of Cardiovascular Disease Events? The Answer Is Crystal Clear

Affiliations

¹ A., Charlton, Clinical Pharmacist AHS, Doctor of Pharmacy, DPharm (PhD), P.A. MacMullan, MD, Clinical Associate Professor, Division Chief, Division of Rheumatology, Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
² A., Charlton, Clinical Pharmacist AHS, Doctor of Pharmacy, DPharm (PhD), P.A. MacMullan, MD, Clinical Associate Professor, Division Chief, Division of Rheumatology, Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada. paul.macmullan@ucalgary.ca.

Editorial

Alexandra Charlton et al. J Rheumatol. 2021 Jul.

. 2021 Jul;48(7):965-966.

doi: 10.3899/jrheum.201304. Epub 2021 Mar 15.

¹ A., Charlton, Clinical Pharmacist AHS, Doctor of Pharmacy, DPharm (PhD), P.A. MacMullan, MD, Clinical Associate Professor, Division Chief, Division of Rheumatology, Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
² A., Charlton, Clinical Pharmacist AHS, Doctor of Pharmacy, DPharm (PhD), P.A. MacMullan, MD, Clinical Associate Professor, Division Chief, Division of Rheumatology, Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada. paul.macmullan@ucalgary.ca.

No abstract available

Comment on

Febuxostat Use and Risks of Cardiovascular Disease Events, Cardiac Death, and All-cause Mortality: Metaanalysis of Randomized Controlled Trials.
Deng H, Zhang BL, Tong JD, Yang XH, Jin HM. Deng H, et al. J Rheumatol. 2021 Jul;48(7):1082-1089. doi: 10.3899/jrheum.200307. Epub 2020 Aug 15. J Rheumatol. 2021. PMID: 32801136